Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab Combined With LD TSEBT in MF and SS
NCT04256018Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Mar 2020
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in mycosis fungoides (MF), Sézary syndrome (SS), sponsored by Stanford University. Started Mar 2020; status: recruiting.
02
Drugs
mogamulizumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT04256018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256018.